Asarina Pharma (Hold, TP: SEK9.00) - Q2 in line with expectations
Asarina Pharma reported Q2 results in line with our expectations with no major events during the quarter. Operating costs are likely to continue to decrease as residual costs related to PMDD are gradually phased out. With temporary delays due to Covid-19, the read-out in MM is expected in Q2 2021. The timeline for TS development is intact with expected start in Q1 2021. We estimate the current cash position is sufficient for both development projects and should take the company to mid-2022. With no major share price catalysts in the near term or any new clinical data available, we reiterate our HOLD and SEK9 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.